Lung Clinical Trials
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Lung
| Protocol | COG ARAR2331 |
|---|---|
| Cancer Type: | Lung-Pleuropulmonary Blastoma |
| Fast Facts |
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB) A COG Groupwide Phase 3 Study
Patients must be ≤ 21 years of age at the time of study enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | Alliance A081801 |
|---|---|
| Cancer Type: | resected NSCLC |
| Fast Facts |
Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO
| Protocol | EA5162 |
|---|---|
| Cancer Type: | Advanced NSCLC |
| Fast Facts |
Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR
| Protocol | Alliance A082002 |
|---|---|
| Cancer Type: | Non-Small Cell Lung Cancer |
| Fast Facts |
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
| Protocol | NRG LU008 |
|---|---|
| Cancer Type: | Lung Cancer |
| Fast Facts |
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
| Protocol | EA5221 (ACHIEVE) |
|---|---|
| Cancer Type: | Lung Cancer |
| Fast Facts |
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
| Protocol | SWOG S2414 |
|---|---|
| Cancer Type: | Lung Cancer-Non-Small Cell |
| Fast Facts |
S2414, A RANDOMIZED PHASE III TRIAL INCORPORATING PATHOLOGIC COMPLETE RESPONSE IN PARTICIPANTS WITH EARLY STAGE NON SMALL CELL LUNG CANCER TO OPTIMIZE IMMUNOTHERAPY IN THE ADJUVANT SETTING (INSIGHT)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | SWOG S1827 |
|---|---|
| Cancer Type: | Small Cell Lung |
| Fast Facts |
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
| Protocol | NRG LU007 |
|---|---|
| Cancer Type: | ES-SCLC |
| Fast Facts |
RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC: RAPTOR trial
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | PDM 9846 |
|---|---|
| Cancer Type: | Tissue Procurement |
| Fast Facts |
Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)
Please check out the rare protocol list to locate other studies within this disease site.
| Protocol | LUNG MAP |
|---|---|
| Cancer Type: | NSCLC |
| Fast Facts |
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.
